Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Flare Therapeutics has entered a strategic collaboration with Roche to discover novel small molecules targeting transcription factors in oncology. Flare will receive $70 million upfront, with potential milestone payments exceeding $1.8 billion, plus royalties.

Portfolio Pulse from

November 12, 2024 | 12:15 pm

The article compares Roche Holding AG (RHHBY) and AbbVie (ABBV) to determine which is a better value stock in the Large Cap Pharmaceuticals sector.

Portfolio Pulse from

November 07, 2024 | 6:00 pm

Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are now listed as available by the FDA, potentially ending their shortage status. This could impact compounding pharmacies and patients who rely on compounded versions of these drugs.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:52 pm

Alphabet Inc. shares rose 6% in pre-market trading after reporting better-than-expected Q3 results with $88.27 billion in revenue. Other stocks like Haoxi Health Technology and Snap Inc. also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 10:16 am

Roche's Q3 sales rose 9% to $17.5 billion, driven by Ocrevus and Vabysmo. Roche urges regulators to block Novo Holdings' $16.5B acquisition of Catalent, citing potential negative industry impacts. The acquisition could affect competition in the GLP-1 market, where several companies, including Roche, have therapies in development.

Portfolio Pulse from Vandana Singh

October 23, 2024 | 11:05 pm

Jazz Pharmaceuticals announced positive Phase 3 trial results for its Zepzelca and Tecentriq combination, showing significant improvement in survival rates for extensive-stage small cell lung cancer. The company plans to submit a marketing application in 2025.

Portfolio Pulse from Vandana Singh

October 15, 2024 | 3:50 pm

Genentech's Evrysdi shows promising two-year data for treating Spinal Muscular Atrophy (SMA) in children, with most achieving key mobility milestones. The therapy is non-invasive and approved in over 100 countries.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 6:52 am

Novo Nordisk and Eli Lilly, leaders in the obesity drug market, may face competition from 16 new drugs expected by 2029. Despite their current dominance, new entrants like Roche, Pfizer, and Amgen could shift market dynamics. Analysts suggest Novo and Lilly stocks might be overvalued due to potential market changes.

Portfolio Pulse from Vandana Singh

October 11, 2024 | 6:11 pm

Tempest Therapeutics Inc. (NASDAQ:TPST) stock surged due to a new agreement with Roche Holdings AG to advance a Phase 3 trial for liver cancer treatment. The trial will evaluate the combination of amezalpat with atezolizumab and bevacizumab. Tempest retains all rights to amezalpat, and the stock rose 23% in premarket trading.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 1:06 pm

Tempest Therapeutics has entered into an agreement with Roche to advance the evaluation of a combination therapy involving amezalpat and atezolizumab. Tempest will lead the pivotal study, while Roche will supply atezolizumab. Tempest retains all rights to amezalpat.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.